Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ling Yui Holdings Limited ( (HK:0784) ) just unveiled an update.
Ling Yui Holdings Limited has strengthened its leadership team by appointing HI Group co-founders Dr. Xu Mingyan and Dr. Chen Shifu as executive directors with effect from 11 May 2026, following a recent composite offer process involving Hapbiotech Investment Holding Limited. Dr. Xu, a biomedical scientist with experience in DNA synthesis technology, and Dr. Chen, an expert in CUDA parallel computing, software engineering and intelligent systems, bring complementary scientific and technological expertise that is expected to enhance the company’s operational oversight and innovation capacity, with both receiving three-year appointments, standard board-linked re-election terms and remuneration aligned with market benchmarks.
More about Ling Yui Holdings Limited
Ling Yui Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates through its association with HI Group, a biotech-focused platform led by experienced scientists and technology specialists. The group’s capabilities span biomedical science, diagnostic development and advanced computing, positioning it at the intersection of biotechnology and artificial intelligence applications.
Average Trading Volume: 12,741,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$704M
Find detailed analytics on 0784 stock on TipRanks’ Stock Analysis page.